Pulse methylprednisolone in rheumatoid arthritis: a double-blind cross-over trial. Liebling MR, Leib E, McLaughlin K, Blocka K, Furst DE, Nyman K, Paulus HE.Links to PubMed are also available for Selected References. Get a printable copy (PDF file) of the complete article (559K), or click on a page image below to browse page by page. Full textįull text is available as a scanned copy of the original print version. In an endeavour to obtain a significant conclusion further patients will now be entered into this study. The clinical response was clearly better in the steroid group with statistical significance almost being achieved. Minor side effects occurred more commonly in the placebo group. These small numbers were not significantly different. Two patients in the steroid group were withdrawn owing to gold induced side effects while four were withdrawn in the placebo group. Twelve patients were withdrawn before completion of the study and all but one of the remaining 28 patients reported clinical and serological improvements. All patients were assessed clinically and serologically over a 24 week period. During the first three months of gold treatment group 1 received monthly intravenous methylprednisolone pulsing (steroid group) while group 2 received placebo (placebo group). Methylprednisolone Mitoxantrone Secondary Progressive Multiple Sclerosis, MS therapy.To test the hypothesis that early steroid pulsing augments the efficacy and decreases the toxicity of chrysotherapy 40 patients with rheumatoid arthritis were studied in a double blind, placebo controlled study. 0.43, P = 0.624).Ĭorticosteroid pulse therapy in SPMS was effective in inflammatory process, but could not postpone or decline the neurodegenerative process and besides the imposing side effects could not result in significant improvement in EDSS and MRI plaques number in long term. Six months after trial completion, EDSS increased in groups without significant difference (0.35 vs. The mean value of EDSS showed significant reduction at the end of treatment in groups (0.79 and 0.53) without significant difference between the groups (P = 0.953). Six months after trial completion, plaques number increased in groups without significantly difference (0.72 vs. 2.17) without significant difference between the groups (P = 0.782). MRI plaques number reduced in groups significantly (2.29 vs. Expanded disability status scale (EDSS), MRI plaques in both groups before and after the treatment completion and six months after the end of trial were compared together.Ģ8 men and 43 women enrolled in the study. The second group (36 patients) received the same dosage of mitoxantrone plus 100 CC of 5% dextrose water monthly for six months. The first group (35 patients) received 20 mg mitoxantrone plus 500 mg methylprednisolone monthly for six months. To evaluate the role of corticosteroid pulse therapy in patients with SPMS receiving mitoxantrone.Ī double blind randomized controlled clinical trial was performed on 71 patients with SPMS referred to Shahid Sadoughi Hospital (Yazd, Iran) for receiving mitoxantrone in two groups. Mitoxantrone has been approved for secondary progressive MS (SPMS) treatment but data lacks the role of corticosteroid pulse therapy in SPMS. Multiple sclerosis (MS) is a central nervous system disorder with periods of recurrence and recovery.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |